Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 01 04:00PM ET
24.50
Dollar change
+1.17
Percentage change
5.02
%
IndexRUT P/E- EPS (ttm)-3.26 Insider Own14.30% Shs Outstand109.56M Perf Week13.53%
Market Cap2.68B Forward P/E- EPS next Y-3.39 Insider Trans-1.24% Shs Float93.90M Perf Month20.39%
Income-331.34M PEG- EPS next Q-0.91 Inst Own97.09% Short Float / Ratio17.30% / 6.55 Perf Quarter-30.10%
Sales26.17M P/S102.57 EPS this Y-14.68% Inst Trans7.86% Short Interest16.25M Perf Half Y-4.18%
Book/sh7.65 P/B3.20 EPS next Y4.13% ROA-36.61% Target Price33.62 Perf Year3.86%
Cash/sh7.42 P/C3.30 EPS next 5Y- ROE-43.63% 52W Range15.44 - 35.60 Perf YTD2.85%
Dividend- P/FCF- EPS past 5Y-39.15% ROI-37.04% 52W High-31.18% Beta1.50
Dividend %- Quick Ratio9.64 Sales past 5Y24.56% Gross Margin65.42% 52W Low58.68% ATR1.44
Employees246 Current Ratio9.64 Sales Q/Q-100.00% Oper. Margin-1409.77% RSI (14)60.70 Volatility4.55% 5.59%
OptionableYes Debt/Eq0.08 EPS Q/Q-14.66% Profit Margin-1266.19% Rel Volume0.61 Prev Close23.33
ShortableYes LT Debt/Eq0.07 EarningsNov 06 AMC Payout- Avg Volume2.48M Price24.50
Recom1.33 SMA2014.81% SMA502.37% SMA200-4.39% Volume1,505,692 Change5.02%
Date Action Analyst Rating Change Price Target Change
Nov-16-23Initiated Raymond James Outperform $30
Feb-28-23Upgrade JP Morgan Neutral → Overweight $32 → $38
Dec-14-22Initiated Needham Buy $31
Oct-21-22Initiated Oppenheimer Outperform $30
May-20-22Initiated BofA Securities Neutral $24
Mar-01-22Upgrade Stifel Hold → Buy $36 → $26
Sep-23-21Initiated Stifel Hold $34
Aug-12-21Downgrade Goldman Buy → Neutral $49 → $27
May-18-21Initiated Goldman Buy $49
May-21-20Initiated H.C. Wainwright Buy $55
Nov-09-23 09:10AM
Nov-08-23 11:30AM
Nov-07-23 10:14AM
Nov-06-23 05:50PM
04:55PM
04:05PM Loading…
04:05PM
Nov-01-23 07:00AM
Oct-31-23 04:15PM
Oct-23-23 04:06PM
01:48PM
12:04PM
10:07AM
Oct-22-23 02:30AM
Oct-19-23 07:02AM
Oct-16-23 03:19PM
09:45AM Loading…
09:45AM
Oct-13-23 02:54PM
11:50AM
Oct-04-23 04:05PM
Sep-20-23 07:01AM
Sep-19-23 07:00AM
Aug-17-23 04:05PM
Aug-09-23 02:13PM
Aug-08-23 05:50PM
04:05PM
Aug-03-23 04:05PM
Aug-01-23 02:34PM
07:00AM
Jul-06-23 09:59AM
Jun-09-23 08:29AM
04:05PM Loading…
Jun-08-23 04:05PM
May-24-23 04:05PM
May-13-23 08:19AM
May-10-23 06:10AM
May-09-23 09:40AM
May-08-23 05:25PM
04:02PM
May-03-23 10:00AM
09:55AM
May-01-23 04:05PM
10:01AM
Apr-19-23 07:15AM
Apr-13-23 04:05PM
Apr-06-23 07:00AM
Mar-22-23 11:29AM
Mar-11-23 03:27AM
Mar-07-23 04:02PM
Mar-02-23 09:15PM
Mar-01-23 04:17PM
Feb-27-23 06:25PM
04:05PM
Feb-21-23 04:05PM
Feb-02-23 12:00PM
07:00AM
Jan-23-23 05:31AM
Jan-12-23 03:25AM
Jan-03-23 07:00AM
Dec-31-22 06:15AM
Dec-26-22 08:14AM
Dec-19-22 07:00AM
Dec-08-22 06:19AM
Dec-07-22 04:05PM
Nov-10-22 05:48AM
Nov-09-22 04:05PM
Nov-07-22 05:55PM
04:05PM
Nov-02-22 10:01AM
09:54AM
Nov-01-22 04:05PM
Oct-24-22 11:07AM
Oct-13-22 11:05AM
Sep-22-22 07:00AM
Sep-01-22 04:05PM
Aug-31-22 04:05PM
Aug-30-22 09:55AM
Aug-12-22 09:55AM
Aug-10-22 08:35AM
Aug-09-22 06:15PM
04:02PM
Jul-28-22 04:02PM
Jul-22-22 04:02PM
Jul-19-22 10:41PM
04:01PM
07:16AM
Jul-13-22 07:00AM
Jun-28-22 07:00AM
Jun-24-22 09:42AM
Jun-09-22 04:02PM
May-11-22 06:22AM
May-09-22 05:35PM
04:02PM
May-06-22 09:50AM
May-05-22 08:05PM
Apr-21-22 04:05PM
Apr-04-22 07:45AM
Mar-31-22 08:33AM
Mar-28-22 04:40PM
Mar-09-22 07:30AM
Mar-01-22 04:05PM
Feb-28-22 06:05PM
Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cislini JeffGeneral CounselNov 20Sale21.701,50032,54538,513Nov 20 06:24 PM
Horn Margaret AChief Operating OfficerOct 25Option Exercise0.547,5004,050104,460Oct 25 06:20 PM
GOLDSMITH MARK ASee RemarksOct 24Option Exercise0.4935,00017,150384,332Oct 24 07:21 PM
Anders JackChief Financial OfficerOct 23Option Exercise2.9824,52472,96778,191Oct 23 06:01 PM
Horn Margaret AChief Operating OfficerOct 16Option Exercise4.0925,000102,250121,960Oct 18 04:23 PM
Horn Margaret AChief Operating OfficerOct 16Sale33.9525,000848,80696,960Oct 18 04:23 PM
Kelsey Stephen MichaelSee RemarksOct 11Sale29.0516,667484,130273,721Oct 13 04:20 PM
Cislini JeffGeneral CounselSep 28Sale28.202,00056,39440,013Oct 02 04:12 PM
GOLDSMITH MARK ASee RemarksSep 18Sale31.318,054252,175349,332Sep 20 04:12 PM
Horn Margaret AChief Operating OfficerSep 18Sale31.312,51478,71596,960Sep 19 04:17 PM
Kelsey Stephen MichaelSee RemarksSep 18Sale31.312,06064,500290,388Sep 20 04:13 PM
Anders JackChief Financial OfficerSep 18Sale31.311,42744,68053,667Sep 20 04:11 PM
Cislini JeffGeneral CounselSep 18Sale31.311,21438,01142,013Sep 20 04:11 PM
Horn Margaret AChief Operating OfficerSep 15Option Exercise4.095,00020,450104,474Sep 19 04:17 PM
Horn Margaret AChief Operating OfficerSep 15Sale32.085,000160,40899,474Sep 19 04:17 PM
Weber BarbaraDirectorSep 01Option Exercise3.8015,00057,03730,825Sep 06 08:03 PM
Anders JackChief Financial OfficerSep 01Option Exercise2.6820,00053,60075,094Sep 06 08:02 PM
GOLDSMITH MARK ASee RemarksSep 01Option Exercise0.7730,00023,164387,386Sep 06 08:05 PM
GOLDSMITH MARK ASee RemarksSep 01Sale35.0530,0001,051,563357,386Sep 06 08:05 PM
Anders JackChief Financial OfficerSep 01Sale35.0520,000701,09255,094Sep 06 08:02 PM
Weber BarbaraDirectorSep 01Sale35.0715,000526,00015,825Sep 06 08:03 PM
GOLDSMITH MARK ASee RemarksSep 01Sale35.0410,000350,41035,424Sep 06 08:05 PM
Horn Margaret AChief Operating OfficerAug 31Option Exercise4.0910,00040,900109,474Sep 01 04:16 PM
Horn Margaret AChief Operating OfficerAug 31Sale34.0510,000340,45899,474Sep 01 04:16 PM
Horn Margaret AChief Operating OfficerAug 15Option Exercise4.095,00020,450104,474Aug 17 04:17 PM
Horn Margaret AChief Operating OfficerAug 15Sale30.535,000152,63299,474Aug 17 04:17 PM
Kelsey Stephen MichaelSee RemarksAug 02Sale32.4016,666539,978292,448Aug 03 04:17 PM
Kelsey Stephen MichaelSee RemarksAug 01Sale29.1916,666486,502309,114Aug 03 04:17 PM
Cislini JeffGeneral CounselJul 31Sale26.021,50039,03043,227Aug 01 06:23 PM
Kelsey Stephen MichaelSee RemarksJun 20Sale24.892,10252,321325,780Jun 22 04:26 PM
Horn Margaret AChief Operating OfficerJun 20Sale24.892,10252,32199,474Jun 22 04:26 PM
Cislini JeffGeneral CounselJun 20Sale25.141,23931,14844,727Jun 22 04:24 PM
Anders JackChief Financial OfficerJun 20Sale24.891,24931,08955,094Jun 22 04:25 PM
Kelsey Stephen MichaelSee RemarksMar 17Sale21.781,23026,789326,369Mar 21 08:33 PM
Horn Margaret ASee RemarksMar 17Sale21.781,23026,789100,062Mar 21 08:33 PM
Wang XiaolinSee RemarksMar 17Sale21.7871415,55158,813Mar 21 08:32 PM
Anders JackChief Financial OfficerMar 17Sale21.7866514,48455,233Mar 21 08:33 PM
Schroeder ThiloDirectorMar 10Buy20.46100,0002,045,6041,553,134Mar 10 07:00 PM
Schroeder ThiloDirectorMar 07Buy22.00550,00012,100,0001,453,134Mar 10 07:00 PM
GOLDSMITH MARK ASee RemarksFeb 22Option Exercise0.4945,00022,050251,872Feb 23 07:33 PM
Kelsey Stephen MichaelSee RemarksDec 19Sale22.941,22027,986287,599Dec 21 04:06 PM
Horn Margaret ASee RemarksDec 19Sale22.941,22027,98561,292Dec 21 04:05 PM
Wang XiaolinSee RemarksDec 19Sale22.9470816,24130,527Dec 21 04:07 PM
Anders JackChief Financial OfficerDec 19Sale22.9465815,09529,298Dec 21 04:08 PM